Fig. 7
From: A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation
Validation of the biomarker in a Japanese cohort (A) shows that the 3-CpG signature shows an accuracy of 87% in classifying SETD2 control and alternative variant cases. (B) shows the true positive and false positive rates of the signature in diagnosing SETD2 control and altered samples in the Japanese cohort. (C) shows boxplots with the methylation distribution of each probe in both the Japanese and TCGA cohorts. Very similar distribution is seen in the SETD2 altered and WT samples in each cohort. All three probes show hypomethylation in SETD2 altered samples.